GeneGo Licenses MetaCore Data Analysis Suite to AVEO Pharmaceuticals
News Oct 23, 2007
GeneGo, Inc. has announced that they have licensed their MetaCore Data Mining Suite to AVEO Pharmaceuticals. The latest version, MetaCore 4.5, includes GeneGo disease enrichment and functional ontology.
MetaCore has an in depth knowledge base for human diseases and the ability to concurrently visualize gene expression, proteomics, genetic and metabolic data. The suite's data management system is designed for automated upload and handling of hundreds to thousands of genome-wide files, which makes MetaCore a robust OMICs repository platform of choice. MetaCore is used in both research and clinical groups in drug development.
"We are pleased that AVEO chose the MetaCore suite of products to enhance its analytical capabilities," says Julie Bryant, Vice President of GeneGo. "AVEO's vision and focus in cancer drug research and development is inspiring and we believe our MetaCore suite of data mining tools will be an asset to their efforts."
Hay Fever Risk Genes Overlap with Autoimmune DiseaseNews
In a large international study involving almost 900,000 participants, researchers from the University of Copenhagen and COPSAC have found new risk genes for hay fever. It is the largest genetic study so far on this type of allergy, which affects millions of people around the world.READ MORE
Hidden Signals in RNAs Regulate Protein SynthesisNews
Scientists have long known that RNA encodes instructions to make proteins. In a new study published in Nature, scientists describe how the protein-making machinery identifies alternative initiation sites from which to start protein synthesis.READ MORE
ExPecto Patronum! Magical Machine Learning Tool Summons DNA Dark Matter DataNews
A new machine learning framework, dubbed ExPecto, can predict the effects of mutations in the so-called “dark matter” regions of the human genome. ExPecto pinpoints how mutations can disrupt the way genes turn on and off throughout your body.